Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Shares Issued (2019 - 2025)

Historic Shares Issued for Dianthus Therapeutics (DNTH) over the last 6 years, with Q3 2025 value amounting to $271.7 million.

  • Dianthus Therapeutics' Shares Issued rose 9168006.76% to $271.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $310.9 million, marking a year-over-year increase of 5052768.73%. This contributed to the annual value of $39.2 million for FY2024, which is 78390000.0% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Shares Issued of $271.7 million as of Q3 2025, which was up 9168006.76% from $470000.0 recorded in Q2 2025.
  • Dianthus Therapeutics' Shares Issued's 5-year high stood at $271.7 million during Q3 2025, with a 5-year trough of -$1.1 million in Q2 2022.
  • Moreover, its 4-year median value for Shares Issued was $200000.0 (2024), whereas its average is $31.0 million.
  • Over the last 5 years, Dianthus Therapeutics' Shares Issued had its largest YoY gain of 9168006.76% in 2025, and its largest YoY loss of 5239.85% in 2025.
  • Quarter analysis of 4 years shows Dianthus Therapeutics' Shares Issued stood at -$49000.0 in 2022, then surged by 110.2% to $5000.0 in 2023, then surged by 771620.0% to $38.6 million in 2024, then soared by 604.06% to $271.7 million in 2025.
  • Its Shares Issued stands at $271.7 million for Q3 2025, versus $470000.0 for Q2 2025 and $129000.0 for Q1 2025.